<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200261</url>
  </required_header>
  <id_info>
    <org_study_id>5081-Ⅰ-1005</org_study_id>
    <nct_id>NCT04200261</nct_id>
  </id_info>
  <brief_title>Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects</brief_title>
  <official_title>Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sihuan Pharmaceutical Holdings Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sihuan Pharmaceutical Holdings Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the pharmacokinetic profiles of benapenem and its major metabolites in healthy
      volunteers after continuous multiple-dose benapenem, providing evidence for phase Ⅱ/Ⅲclinical
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t) of Benapenem</measure>
    <time_frame>Pre dose and 0.25,1,1.25,1.5, 2, 3,5,8,12, 24,72,96,120,144,144.5,145,145.25,145.5,146,147,149,152,156,168,180,192hours after first Dosing</time_frame>
    <description>AUC(0-t) is the area under the curve from time 0 to t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Benapenem</measure>
    <time_frame>Pre dose and 0.25,1,1.25,1.5, 2, 3,5,8,12, 24,72,96,120,144,144.5,145,145.25,145.5,146,147,149,152,156,168,180,192hours after first Dosing</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Benapenem in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (tmax) of Benapenem</measure>
    <time_frame>Pre dose and 0.25,1,1.25,1.5, 2, 3,5,8,12, 24,72,96,120,144,144.5,145,145.25,145.5,146,147,149,152,156,168,180,192hours after first Dosing</time_frame>
    <description>Time to maximum observed plasma concentration (tmax) of Benapenem in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to elimination half-life (t1/2) of Benapenem</measure>
    <time_frame>Pre dose and 0.25,1,1.25,1.5, 2, 3,5,8,12, 24,72,96,120,144,144.5,145,145.25,145.5,146,147,149,152,156,168,180,192hours after first Dosing</time_frame>
    <description>Time to elimination half-life (t1/2) of Benapenem in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in vital signs</measure>
    <time_frame>Screening, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10 after Dosing</time_frame>
    <description>Vitals signs such as systolic and diastolic blood pressure, heart rate, and pulse rate will be measured in a semi-supine position after 5 minutes of rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory parameters</measure>
    <time_frame>Screening, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10 after Dosing</time_frame>
    <description>Hematology and Clinical Chemistry and Urine routine abnormalities will be monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant 12-lead ECGs</measure>
    <time_frame>Screening, Day1, Day2, Day4, Day5,Day7, Day8, Day10 after Dosing</time_frame>
    <description>Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events</measure>
    <time_frame>From Screening to Day 10 after dosing</time_frame>
    <description>All adverse events will be monitored in each group subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Banapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sodium chloride injection Once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Banapenem</intervention_name>
    <description>2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed</description>
    <arm_group_label>Banapenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>sodium chloride</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1、 Male or female healthy subjects, aged 18~45(including 18 and 45 years); 2、Body
             weight ≥ 50 kg and body mass index 19.0~24.0 kg/m2; 3、Prior to the test, physical
             examination, blood routine, urine routine, liver and kidney functions, and related
             examinations normal, or mild abnormalities in indicators while without clinical
             significance as indicated by the investigator ; 4、Normal or mild abnormalities without
             clinical significance in the standard 12-lead ECG; 5、 Signing informed consent form.

        Exclusion Criteria:

          -  1、Having a serious systemic disease, infectious disease or mental disorder; 2、Regular
             smoking, alcohol abuse, and drug abuse ; 3、Use of drugs known damage to an organ
             within three months; 4、History of specific allergies, or history of drug allergy,
             especially those allergic to lactams and excipients of test drug; 5、Febrile illnesses
             within three days before the screening; 6、Patients with mental illness or psychotic
             disorder in the past; 7、Past mental and nervous system diseases (epilepsy, stroke,
             cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers,
             gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory,
             hematological, or endocrine system, etc.) diseases or medical history; 8、Habitually
             taking any medication, including traditional Chinese medicine; 9、Having taken any
             medication that may affect test results within two weeks before the screening, such as
             antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics,
             anticoagulants, central nervous system depressants, and any drug that may affect the
             drug absorption; 10、Having participated in other investigational drug trial in the
             preceding three months; 11、Blood donation for 360 ml or more within three months
             before the screening; 12、Heart rate &lt; 50 bpm or &gt; 100 bpm; 13、Systolic blood
             pressure&lt;90mmHg or ≥ 140mmHg, diastolic blood pressure ≥ 90 mmHg or &lt;60mmHg ; 14、Women
             who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable
             contraception, or who have a positive result in serum pregnancy test; 15、Women who are
             planning to become pregnant within 6 months, or male subjects who are planning to make
             his spouse pregnant within 6 months; 16、HBsAg, HCV antibody, HIV antibody, and
             Treponema pallidum antibody positive; 17、Urine drug-of-abuse testing positive; 18、Any
             other factor that makes the subject not suitable for the trial as indicated by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Ten men, ten women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuan lv, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yuan lv, Doctor</last_name>
    <phone>18813015605</phone>
    <email>LYU18813015605@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university first hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Lv, Doctor</last_name>
      <phone>18813015605</phone>
      <email>LYU18813015605@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

